The Implications of Fruit and Vegetable Consumption in Patients with Diabetes



How to Cite

Lee Meier, M., Greenspan, P., A. Keedy, C., & Misher, A. (2021). The Implications of Fruit and Vegetable Consumption in Patients with Diabetes. Journal of Pharmacy and Nutrition Sciences, 11, 28–32.


It is widely accepted that the management of diabetes should include both pharmacologic and lifestyle modifications. However, these recommendations are not readily or consistently incorporated into clinical practice. Current guideline recommendations encourage an emphasis on nutrient-dense foods, which include those foods that tend to be high in flavonoids such as fruits and vegetables. Polyphenolic compounds in fruits and vegetables have been shown to affect the same biological processes as certain classes of pharmacological therapy used in the treatment of diabetes. A better understanding of the benefits of these compounds may help healthcare professionals, including pharmacists, communicate dietary recommendations to patients.


Lifestyle Management: Standards of Medical Care in Diabetes- 2021. American Diabetes Association. Diabetes Care Jan 2019, 42 (Supplement 1) S1-S2;

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan-2015. Endocrine Practice 2015, 21 (Supplement 1).

Mahoney, Sara & Loprinzi, Paul. (2014). Influence of Flavonoid-Rich Fruit and Vegetable Intake on Diabetic Retinopathy and Diabetes-Related Biomarkers. Journal of Diabetes and its Complications. 28.

Du H, Li L, Bennett D, et al. Fresh fruit consumption in relation to incident diabetes and diabetic vascular complications: A 7-y prospective study of 0.5 million Chinese adults. PLoS Med. 2017;14(4):e1002279. Published 2017 Apr 11.

Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne). 2017;8:6. Published 2017 Jan 24.

Ikeda, M., Shimazawa, R. Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes. J Gen Fam Med. 2019; 20(4): 129-138.

Kumar S, Narwal S, Kumar V, Prakash O. α-glucosidase inhibitors from plants: A natural approach to treat diabetes. Pharmacogn Rev. 2011;5(9):19-29.

McDougal, DJ., et al. Different polyphenolic component or soft fruits inhibit alpha-amylase and alpha-glucosidase. J Agric Food Chem. 2005; 53(7): 2760-2766.

Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. 2014;5(2):355-66.

Hardman, TC., Rutherford, P., Dubrey, SW., Wierzbicki, AS., Sodium-glucose co-transporter 2 inhibitors: from apple tree to ‘sweet pee.’ Curr Pharm Des. 2010: 16(34): 3830-3838.

Tian C, Ye X, Zhang R, Long J, Ren W, et al. Green Tea Polyphenols Reduced Fat Deposits in High Fat-Fed Rats. PLOS ONE. 2015; 8(9): 10.

Hurtado de llera A, Martin-hidalgo D, Rodriguez-gil JE, Gil MC, Garcia-marin LJ, Bragado MJ. AMP-activated kinase, AMPK, is involved in the maintenance of plasma membrane organization in boar spermatozoa. Biochim Biophys Acta. 2013;1828(9):2143-51.

Sharma, C., et al. Advanced glycation end-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol. 2015; 52(12): 7561-7576.

Tessier FJ. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol (Paris) . 2010;58:214–9.

Ansari, Nadeem & Moinuddin, Anis Shaikh & Mir, Abdul Rouf & Habib, Safia & Alam, Khursheed & Ali, Asif & Khan, Rizwan Hasan. (2014). Role of Early Glycation Amadori Products of Lysine-Rich Proteins in the Production of Autoantibodies in Diabetes Type 2 Patients. Cell biochemistry and biophysics. 70.

Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18(1):1-14.

Banser, A., Naafs, J., et al. Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus. Pediatr Diabetes. 2016; 17(6): 426-432.

Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab. 2013;3(2):94-108. Published 2013 Dec 7.

Fishman, SL., Sonmez, H., et al. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med 2018; 59(24).

Kong, Y., Liu, C., Progress of RAGE molecular imaging in Alzheimer’s Disease. Front Aging Neurosci. 2020; 12(227).

Asadipooya, K., Mae EU. Advanced glycation end products (AGEs), receptor for AGEs, diabetes, and bone: review of the literature. Journal of the Endocrine Society. 2019; 3(10): 1799-1818.

Luevano-Contreras, C., Chapman, K. Dietary advanced glycation endproducts and aging. Nutrients. 2010: 2(12): 1247-1265.

Sanguineti, R., et al. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm. 2014; 2014: 975872.

Zhou, Z., Xiong, WC. RAGE and its ligands in bone metabolism. 2011; 3: 768-776.

Uribarri, J., Woodruff, S., et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010; 110(6): 911-916.

Gkogkolou P, Böhm M. Advanced glycation end products: Key players in skin aging? Dermatoendocrinol. 2012;4(3):259-70.

Chen, JH., Lin, X., et al. Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. Nutr Metab. 2018; 15:72.

Gruyter, D. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy. BioMol Concepts. 2016: 7(5): 293-309.

Perrone, A., et al. Advanced glycation end products (AGE): biochemistry, signaling, analytical methods, and epigenetic effects. Oxid Med Cell Longev. 2020; 2020.

Ashraf, JM., et al. Recent advanced in detection of AGEs: immunochemical, bioanalytical and biochemical approaches. IUBMB Life. 2015: 67(12): 897-913.

Suantawee, T., et al. Protein glycation inhibitor activity and antioxidant capacity of clove extract. J Food Sci Tenchnol. 2015; 52(6): 3843-3850.

Rubio-Ruiz, ME., Glycation does not modify bovine serum albumin (BSA)-induced reduction of rat aortic relaxation: The response to glycated and nonglycated BSA is lost in metabolic syndrome. Glycobiology. 2008; 18(7): 517-525.

Kinoshita, S., et al. Nω-(Carboxymethyl)arginine is one of the dominant advanced glycation end products in glycated collagens and mouse tissues. Oxidative Medicine and Cellular Longevity. 2019.

Salahuddin P, Rabbani G, Hasan Khan R. The role of advanced glycation end products in various -types of neurodgenerative disease: A therapeutic approach. Cell Mol Biol Lett.2014; 19: 407-437.

Sadowska-Bartosz, I., et al. Kinetics of glycoxidation of bovine serum albumin by glucose, fructose and ribose and its prevention by food components. Molecules. 2014; 19(11): 18828-18849.

Matsuda, H.; Wang, T.; Managi, H.; Yoshikawa, M. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorg. Med. Chem., 2003, 11, 5317-5323.

Dorsey PG, Greenspan P. Inhibition of nonenzymatic protein glycation by pomegranate and other fruit juices. J Med Food. 2014;17(4):447-54.

Lim, TK. Punica Granatum. Edible Medicinal and Non-Medicinal Plants. 2012;5: 136-194.

Fournet, M., et al. Glycation damage: a possible hub for major pathophysiological disorders and aging. Aging Dis. 2018; 9(5): 880-900.

Mir AR, et al. Methylglyoxal mediated conformational changes in histone H2A-generation of carboxyethylated advanced glycation end products. Int J Biol Macromol, 2014; 69:260-6.

Snedeker, JG., Gautieri, A., The role of collagen crosslinks in aging and diabetes – the good, the bad, and the ugly. Muscles Ligaments Tensons J. 2014: 4(3): 303-308.

Toprak, C., Yigitaslan, S., Alagebrium and complications of diabetes mellitus. Eurasian J Med. 2019; 51(3): 285-292.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.